Dataset Information

A feasibility study of an integrated couples-based supportive programme for Chinese couples living with colorectal cancer.

ABSTRACT:

Aim

To test the feasibility, acceptability and preliminary efficacy of using an integrated approach combined online and in-person delivery to support colorectal cancer (CRC) patients and their spousal caregivers coping positively with cancer together.

Design

A single-arm pre-post-feasibility design was used.

Methods

Chinese CRC patient-partner dyads (N = 24) accessed the blended intervention combined online platform and face-to-face sessions for six weeks between October 2019 to January 2020. Feasibility was measured through recruitment and retention and acceptability was examined by intervention engagement and post-treatment programme evaluation. Effect sizes were calculated using the complete data (N = 20 couple dyads) to evaluate preliminary treatment effect.

Results

Recruitment (70.6%) and retention rates (83.3%) supported programme feasibility. Participants' positive intervention engagements and evaluations indicated acceptability. The overall small-to-medium improvements in most outcome measures verified preliminary efficacy of the integrated couples-based supportive programme. The findings support its feasible and acceptable for couples coping with CRC and show potential efficacy.

SUBMITTER: Luo X

PROVIDER: S-EPMC7877155 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A feasibility study of an integrated couples-based supportive programme for Chinese couples living with colorectal cancer.

Luo Xingjuan X Li Jieyu J Cao Qian Q Sun Liya L Chen Ying Y Zhao Jie J Li Qiuping Q

Nursing open 20201126 2

<h4>Aim</h4>To test the feasibility, acceptability and preliminary efficacy of using an integrated approach combined online and in-person delivery to support colorectal cancer (CRC) patients and their spousal caregivers coping positively with cancer together.<h4>Design</h4>A single-arm pre-post-feasibility design was used.<h4>Methods</h4>Chinese CRC patient-partner dyads (N = 24) accessed the blended intervention combined online platform and face-to-face sessions for six weeks between October 20 ...[more]

PMID: 33570269

Similar Datasets

Project description:IntroductionPharmacogenomics is about selecting the "right drug in the right amount for the right patient." In metastatic colorectal cancer, germline pharmacogenomics testing presents a unique opportunity to improve outcomes, since the genes dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase metabolizing the chemotherapy drugs, 5-fluorouracil, and irinotecan are already well known. In a retrospective analysis of the landmark TRIBE clinical trial [(TRIBE - TRIplet plus BEvacizumab multicenter, phase III trial by the Italian Cooperative GONO (Gruppo Oncologico Nord Ovest) group (NCT00719797)], the proportion of patients with serious adverse events was higher in those with dihydropyrimidine dehydrogenase/UDP-glucuronosyltransferase aberrations and was dose dependent. We aimed to report on the feasibility and the results of incorporating pharmacogenomics testing into clinical practice.MethodsAs a quality improvement initiative and a center of individualized medicine grant, we integrated the use of OneOme RightMed comprehensive test, which reports on 27 genes related to pharmacogenomics and over 300 medications of interest. We limited initial testing to patients with colorectal cancer. Pharmacists provided dosage recommendations based on test results in real-time.ResultsAt our cancer center, 155 patients underwent pharmacogenomics testing from November 2017 to January 2019. Results were available within 3 to 5 days of testing for most patients and were integrated into treatment decision-making. Of 155 sampled participants, a total of 89 (57.4%) participants had an UGT1A1 variant genotype, NM_000463.2: c.-53_-52[8] *1/*28, n = 74 (47.7%); *28/*28, n = 15 (9.7%). Additionally, 4 (2.6%) participants were heterozygous for dihydropyrimidine dehydrogenase. Two (1.3%) individuals were heterozygous for both UDP-glucuronosyltransferase and dihydropyrimidine dehydrogenase genes. All (100%) the patients had at least 1 actionable aberration related to supportive care medications (CYP-family) of all the possible medications listed on their pharmacogenomics report.ConclusionPreemptive comprehensive pharmacogenomics testing can be integrated into clinical practice in real-time for patients with cancer given faster turnaround and low cost. Pharmacist-driven, patient-specific medication management consults add further value given the number of genes/drugs. This sets the stage for a prospective randomized clinical trial to demonstrate the amount of benefit this can result in these patients.

Project description:ObjectivesTo determine acceptability and feasibility of a theatre-based wellness programme to support the health and well-being of people with long COVID.DesignSingle-group, repeated-measures feasibility study.SettingCommunity centre and online.ParticipantsAdults with diagnosed long COVID experiencing breathlessness, pain and/or loneliness.InterventionSix-week participatory creative programme delivered to one online and one in-person group facilitated by movement, voice and drama consultants using breathing, visualisation, singing, poetry, storytelling and movement exercises.Primary outcome measuresProgramme acceptability and feasibility measured via uptake, reasons for non-attendance and barriers to engagement.Secondary outcome measuresFeasibility of recruitment and data collection procedures measured through proportion of missing data and follow-up rates, mechanisms of action of the programme identified through qualitative interviews, changes in mental health, well-being, quality of life, loneliness, social support, fatigue, breathlessness and post-COVID-19 functional status at 8-week follow-up.Results21 people expressed interest in participating, 20 people took part in the programme, 19 completed baseline and 16 completed follow-up assessments. Participants attended an average of 4.8 of 6 sessions (SD=1.5, range 2-6). Exploratory analyses demonstrated significant improvements in self-rated health (t-test mean difference=0.12, 95% CI=0.00, 0.23, p=0.04) and chronic fatigue symptoms (mean difference=-3.50, 95% CI=-6.97, -0.03, p=0.05) at 8 weeks. Key mechanisms of action that supported health and well-being included: increased sense of community, illness acceptance, experiencing joy, increased confidence in managing everyday life, increased ability to relax and reconnection with previous identity. Barriers to engagement included: activities being outside of the participant's comfort zone, ongoing long COVID symptoms, emotional consequences of sharing experiences and connectivity and connecting online.ConclusionsA 6-week theatre-based programme was perceived as acceptable to most participants and resulted in some positive psychosocial impacts. The findings provide a rationale for supporting the ongoing development and scale-up of this and related arts programmes to support people living with long COVID.

Project description:BackgroundCancer supportive care interventions often have limited generalizability, goal misalignment, and high costs. We developed and piloted a health coaching intervention, UNC HealthScore, in patients undergoing cancer treatment (ClinicalTrials.gov identifier NCT04923997). We present feasibility, acceptability, and preliminary outcome data.MethodsHealthScore is a six-month, theory-based, multicomponent intervention delivered through participant-driven coaching sessions. For the pilot study, participants were provided a Fitbit, responded to weekly symptom and physical function digital surveys, and met with a health coach weekly to develop and monitor goals. Coaching notes were discussed in weekly interdisciplinary team meetings and provided back to the treating oncology team. Symptom alerts were monitored and triaged through a study resource nurse to relevant supportive care services. Feasibility was determined based on intervention enrollment and completion. Acceptability was based on satisfaction with coaching and Fitbit-wearing and was informed by semistructured exit interviews. Outcomes evaluated for signs of improvement included several PROMIS (Patient-Reported Outcomes Measurement Information System) measures, including the primary intervention target, physical function.ResultsFrom May 2020 to March 2022, 50 participants completed the single-arm pilot. Feasibility was high: 66% enrolled and 71% completed the full intervention. Participants reported an average of 4.8 and 4.7 (out of 5) on the acceptability of coaching calls and using the Fitbit, respectively. Physical function scores rose 3.1 points (SE = 1.1) from baseline to 3 months, and 4.3 (SE = 1.0) from baseline to 6 months, above established minimal clinically important difference (MCID). Improvements above MCID were also evident in anxiety and depression, and smaller improvements were demonstrated for emotional support, social isolation, cognitive function, symptom burden, and self-efficacy.DiscussionHealthScore shows feasibility, acceptability, and promising preliminary outcomes. Randomized studies are underway to determine the efficacy of preserving physical function in patients with advanced cancer.

Dataset Information

A feasibility study of an integrated couples-based supportive programme for Chinese couples living with colorectal cancer.

Aim

Design

Methods

Results

Publications

A feasibility study of an integrated couples-based supportive programme for Chinese couples living with colorectal cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets